medigraphic.com
Revista Médica Sinergia

2024, Number 08

<< Back Next >>

Revista Médica Sinergia 2024; 9 (08)

Update on the diagnostic and therapeutic approach to transthyretin cardiac amyloidosis: an underestimated entity

López BVM, Chacón QMM, Apuy RF, Sáenz MME

Language: Spanish
References: 25
Page:
PDF size: 183.45 Kb.


ABSTRACT

Cardiac amyloidosis (CA) is a serious condition that affects heart function due to the abnormal deposition of amyloid. It can be caused by different types of proteins, with the most common being light chains (AL) and transthyretin (ATTR) in its hereditary (ATTRv) and non-hereditary (ATTRwt) forms. The ATTRwt variant is the most prevalent, and its early diagnosis poses a challenge due to the variability of clinical manifestations and the lack of specific diagnostic tests. Thus, the classic phenotype of CA is heart failure with preserved ejection fraction (HFpEF). Diagnostic suspicion is based on clinical, electrocardiographic, and echocardiographic findings; with magnetic resonance imaging, bone scintigraphy with bisphosphonates, and determination of monoclonal components in blood and/or urine reserved for confirmation. Additionally, cardiac rhythm disorders, syncope, and aortic valve disease are also frequent manifestations of CA. Treatment involves managing cardiac complications (supportive care) and the amyloidogenic process (specifically). It is worth noting that recent advances in diagnostic processes and new therapies available translate into improvements in patient prognosis. This review aims to synthesize the diagnostic and therapeutic approach to ATTR-CA.


REFERENCES

  1. Combarro M, González E, Martínez A, Barge G. Actualización en el abordaje diagnóstico y terapéutico de la amiloidosis cardiaca por transtirretina. REC CardioClinics. 2022;57(S2):S19-S27. DOI: https://doi.org/10.1016/j.rccl.2022.07.006

  2. García J, Rodríguez C. Amiloidosis cardiaca: estudio de caso y revisión bibliográfica. Rev Costarric Salud Pública. 2019;28(1):74-82. Disponible a partir de: http://www.scielo.sa.cr/scielo.php?script=sci_arttext&pid=S1409-14292019000100074&lng=en

  3. Rubin J, Maurer MS. Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable. Annu Rev Med. 2020;71:203-219. DOI: https://doi.org/10.1146/annurev-med-052918-020140

  4. Kittleson M, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ, Nair AP, Nativi-Nicolau J, Ruberg FL. Cardiac Amyloidosis: Evolving Diagnosis and Management. A Scientific Statement from the American Heart Association. 2020;142:e7-e22. DOI: https://doi.org/10.1161/cir.0000000000000792

  5. Porcari A, Fontana M, Gillmore JD. Transthyretin cardiac amyloidosis. Cardiovascular Research. 2022;118:3517-3535. DOI: https://doi.org/10.1093/cvr/cvac119

  6. Gertz M. Cardiac Amyloidosis. Heart Fail Clin. 2022;18(3):479-488. DOI: 10.1016/j.hfc.2022.02.005.

  7. Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, Burazor I, Caforio ALP, Damy T, Eriksson U, Fontana M, Gillmore JD, Gonzalez-Lopez E, Grogan M, Heymans S, Imazio M, Kindermann I, Kristen AV, Maurer MS, Merlini G, Pantazis A, Pankuweit S, Rigopoulos AG, Linhart A. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021;42(16):1554-1568. DOI: https://doi.org/10.1093%2Feurheartj%2Fehab072.

  8. Yamamoto H, Yokochi T. Transthyretin cardiac amyloidosis: an update on diagnosis and treatment. ESC Heart Failure. 2019;6:1128-1139. DOI: 10.1002/ehf2.12518

  9. Hartnett J, Jaber W, Maurer M, Sperry B, Hanna M, Collier P, Patel DR, Wazni OM, Donnellan E. Electrophysiological Manifestations of Cardiac Amyloidosis. JACC CardioOncoloy. 2021;3(4):506-515. DOI: https://doi.org/10.1016/j.jaccao.2021.07.010

  10. Martínez F, Báez A. Aportes del ecocardiograma y las técnicas de deformación miocárdica en la amiloidosis cardíaca. Bases de la técnica y hallazgos de utilidad diagnóstica. Rev Urug Cardiol. 2023;38:e301-e307. DOI: 10.29277/cardio.38.1.11

  11. Pudis M, Bastarrika AG. Papel actual de las técnicas de imagen en la amiloidosis cardíaca. Medicina Clínica. 2023;160:121-128. DOI: https://doi.org/10.1016/j.medcli.2022.09.010

  12. Pérez AD, Baratta S, Campisi R, Cerda M, Aguirre A, Villanueva E, Fernández A, Belziti C. Imágenes en la amiloidosis cardíaca. Rev Argent Cardiol. 2021;89:253-261. DOI: http://dx.doi.org/10.7775/rac.es.v89.i3.20394

  13. Witteles RM, Liedtke M. AL Amyloidosis for the Cardiologist and Oncologist: Epidemiology, Diagnosis, and Management. JACC CardioOncology. 2019;1(1):117-130. DOI: https://doi.org/10.1016/j.jaccao.2019.08.002

  14. Castañía F, Massardo T, Álvarez J, Jalil J, Greig D, Mcnab P, Llancaqueo M, Jaimovich R. Cardiomiopatía amiloidea por transtiretina: diagnóstico y manejo en la actualidad. Rev Chil Cardiol. 2021;40(2):148-160. DOI: http://dx.doi.org/10.4067/S0718-85602021000200148

  15. Donnellan E, Wazni OM, Hanna M, Kanj M, Saliba WI, Jaber WA. Cardiac Resynchronization Therapy for Transthyretin Cardiac Amyloidosis. JAHA. 2020;9(14):1-3. DOI: https://doi.org/10.1161/JAHA.120.017335

  16. Rapezzi C, Aimo A, Serenelli M, Barison A, Vergaro G, Passino C, Panichella G, Sinagra G, Merlo M, Fontana M, Gillmore J, Quarta CC, Maurer MS, Kittleson MM, Garcia-Pavia P, Emdin M. Critical Comparison of Documents from Scientific Societies on Cardiac Amyloidosis: JACC State-of-the-Art Review. JACC. 2022;79(13):1288-1303. DOI: https://doi.org/10.1016/j.jacc.2022.01.036

  17. Stern LK, Patel J. Cardiac Amyloidosis Treatment. Methodist DeBakey Cardiovasc J. 2022;18(2):59-72. DOI: https://doi.org/10.14797/mdcvj.1050

  18. Ioannou A, Fontana M, D-Gillmore J. Patisiran for the Treatment of Transthyretin-mediated Amyloidosis with Cardiomyopathy. Heart Int. 2023;17(1):27-35. DOI: https://doi.org/10.17925%2FHI.2023.17.1.27

  19. Adams D, Tournev IL, Taylor MS, Coelho T, Planté-Bordeneuve V, Berk JL, González-Duarte A, Gillmore JD, Low SC, Sekijima Y, Obici L, Chen C, Badri P, Arum SM, Vest J, Polydefkis M. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid. 2023;30(1):1-9. DOI: https://doi.org/10.1080/13506129.2022.2091985.

  20. Ghoneem A, Bhatti AW, Khadke S, Mitchell J, Liu J, Zhang K, Trachtenberg B, Wechalekar A, Cheng RK, Baron SJ, Nohria A, Lenihan D, Ganatra S, Dani SS. Real-World Efficacy of Tafamidis in Patients with Transthyretin Amyloidosis and Heart Failure. Curr Probl Cardiol. 2023;48(6):101667. DOI: https://doi.org/10.1016/j.cpcardiol.2023.101667

  21. Gillmore JD, Judge DP, Cappelli F, Fontana M, Garcia-Parvia P, Gibbs S, Grogan M, Hanna M, Hoffman J, Masri A, Maurer MS, Nativi-Nicolau J, Obici L, Poulsen SH, Rockhold F, Shah KB, Soman P, Garg J, Chiswell K, Xu H, Cao X, Lystig T, Sinha U, Fox JC. Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2024;390(2):132-142. DOI: 10.1056/NEJMoa2305434.

  22. Wu D, Chen W. Molecular mechanisms and emerging therapies in wild-type transthyretin amyloid cardiomyopathy. Heart Failure Reviews. 2024;29:511-521. DOI: https://doi.org/10.1007/s10741-023-10380-9

  23. Lozano BA, Lambarri IA, Escolar PV, Lluis SI. Aproximación diagnóstica a la amiloidosis cardiaca por transtiretina en un área no endémica. ¿Qué variables noinvasivas orientan a su diagnóstico? RevColomb Cardiol. 2021;28(2):197-199. DOI: https://doi.org/10.24875/rccar.m21000033

  24. Manganelli F, Fabrizi GM, Luigetti M, Mandich P, Mazzeo A, Pareyson D. Hereditary transthyretin amyloidosis overview. Neurol Sci. 2022;43(Suppl 2):595-604. DOI: https://doi.org/10.1007/s10072-020-04889-2

  25. Izumiya Y, Hayashi H, Ishikawa H, Shibata A, Yoshiyama M. How to Identify Transthyretin Cardiac Amyloidosis at an Early Stage. Intern Med. 2021;60(1):1-7. DOI: https://doi.org/10.2169/internalmedicine.5505-20




2020     |     www.medigraphic.com